Pre-transfusion screening for platelet-reactive antibodies.
We retrospectively compared the cost of platelet concentrates (PCs) used for patients whose serum had already been screened for platelet-reactive antibodies with the cost for patients whose serum was examined after the commencement of treatment using platelets. On the basis of 774 patients' data, the mean cost of PCs for the latter group of patients ($5562) was higher than that for the former group ($2547). Screening beforehand ensured a prompt supply of specific PCs, and costs were suppressed by the avoidance of multiple transfusions. We conclude that screening for platelet-reactive antibodies followed by administration of crossmatch-negative PCs appears to be both clinically and economically advantageous.
Tasaki
Tetsunori
T
Department of Blood Transfusion and Testing, Iwate Medical University Hospital, Japan. ttasaki@iwate-med.ac.jp
Fujii
Kieko
K
Gotoh
Kenji
K
Satoh
Shukuko
S
Takadate
Junko
J
Sasaki
Sakiko
S
Kamitsukue
Mihoko
M
Yamamoto
Kimiko
K
Suwabe
Akira
A
D001323:Autoantibodies / Q000032:analysis* / Q000276:immunology; D001792:Blood Platelets / Q000276:immunology; D001793:Blood Preservation / Q000191:economics / Q000379:methods; D003365:Costs and Cost Analysis / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics / Q000379:methods; D017713:Platelet Transfusion / Q000191:economics; D012189:Retrospective Studies
D001323:Autoantibodies